CANCER RESEARCH

CANCER RESEARCH Journal

publication venue for

Effects of plasma exosome isolation methods on detectable multiomic profiles in cancer patients and healthy controls 2022
Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5). 2021
A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer 2021
Combined use of MammaPrint and BluePrint assays to evaluate patients for response to neo-adjuvant chemotherapy for locally advanced breast cancer 2021
Mammaprint and blueprint as prognostic indicators for elderly patients with early stage breast cancer 2021
CRESTONE - Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions - A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). 2020
Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study 2020
Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST-a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC 2019
IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC 2019
A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer 2019
Neoadjuvant chemotherapy for breast cancer: Nodal downstaging is highly correlated with pathological complete response 2019
A phase I study to evaluate next-generation DNA sequencing testing in rectal swabs prior to transrectal prostate biopsy for cancer screening and diagnosis. 2018
IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups 2018
Targeting lysophospholipid metabolism inhibits pancreatic cancer cell proliferation under nutrient-limiting conditions 2018
A phase 2 study of eribulin in breast cancer not achieving a pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) 2016
One-year follow-up results of a multi-center trial of intra-operative radiation therapy using electronic brachytherapy at the time of breast conservation surgery for early stage breast cancer 2016
Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models 2015
Codon 72 and Intron-3 polymorphisms in TP53 are risk factors for breast cancer 2015
Assay Development for detection of estrogen responsive gene histone acetylation in breast cancer circulating tumor cells 2015
Development and implementation of a breast cancer risk identification and reduction program in a large health care system 2015
Pilot study of a passive non-radioactive electromagnetic wave technology to localize non-palpable breast lesions 2015
JQ1 suppresses tumor growth in tumorgraft models of pancreatic ductal adenocarcinoma 2014
Racial disparity in the TP53 mutation spectra in triple-negative breast cancers: Validation with TCGA data 2014
Relevance of Sp1 and survivin expression in epithelial ovarian cancer patients and their usefulness as potential therapeutic targets 2014
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. 74:1214-1226. 2014
Direct comparison of risk classification between MammaPrint (R), Oncotype DX (R) and MammoStrat (R) assays in patients with early stage breast cancer 2013
Ethnicity disparities of breast cancer in an insured population 2013
A phase I trial investigating apoptosis induction with tumor necrosis factor or radiation alone prior to intratumoral injection of autologous dendritic cells in patients with locally advanced or low volume metastatic pancreatic cancer. 2013
Acidity Generated by the Tumor Microenvironment Drives Local Invasion. 73:1524-1535. 2013
MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I 2012
Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer 2012
EGF receptor, Jaks and Stat3 crosstalk promote enhanced colony-forming, motility, migration, and invasive phenotype of cisplatin-resistant ovarian cancer cells 2012
Targeting Sp1 and survivin for potential ovarian cancer therapy: Comparative assessment of anti-cancer NSAID tolfenamic acid and cisplatin 2012
Safety and Efficacy of Neratinib in Combination with Capecitabine in Patients with ErbB2-Positive Breast Cancer 2011
A novel therapeutic compound, tolfenamic acid, inhibits ovarian cancer cell growth: Therapeutic implications 2011
Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models 2011
Receptor Channel TRPC6 Is a Key Mediator of Notch-Driven Glioblastoma Growth and Invasiveness. 70:418-427. 2010
Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study 2009
Prostate derived Ets factor (PDEF), an emerging biomarker in cancer 2009
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer. 2009
Targeting of the Bmi-1 Oncogene/Stem Cell Renewal Factor by MicroRNA-128 Inhibits Glioma Proliferation and Self-Renewal. 68:9125-9130. 2008
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. 68:6734-6742. 2008
Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. 67:9535-9541. 2007
Loss at Chromosome 13q22.2 Indicates Poor Survival in a Group of Grade 2 and Grade 3 Astrocytomas 2006
Cystatin M: A novel candidate tumor suppressor gene for breast cancer. 64:6957-6964. 2004
Mutations in the arginine-rich protein gene, in lung, breast, and prostate cancers, and in squamous cell carcinoma of the head and neck. 56:5576-5578. 1996
Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. 56:4347-4350. 1996

category

ONCOLOGY Web of Science Category

International Standard Serial Number (ISSN)

0008-5472

Electronic International Standard Serial Number (EISSN)

1538-7445

journal abbreviation

CANCER RES